Author: claimsbot

1. A system (1) for processing configuration data of a communication network, characterized in that it includes first calculation means (3) adapted to determine a network usage predictive state from first data representative of the usage of resources andor services within said network and second calculation means (4) adapted to determine a network evolution planning proposal from said usage predictive state and second data representative of plant (Ri, ERj) of said network and said first calculation means (3) are adapted to determine usage profiles of service level agreements (7) between the operator of the network and customers from said first data and from said service level agreements.
2. A system according to claim 1, characterized in that said first calculation means (3) are adapted to determine said network usage predictive state from complementary third data representative of user requirement prediction information.
3. A system according to claim 1, characterized in that said first calculation means (3) are adapted to determine a service level agreement usage profile (7) for each service level agreement.
4. A system according to claim 1, characterized in that said first calculation means (3) are adapted to determine a service level agreement usage predictive profile constituting said network usage predictive state from said service level agreement usage profiles (7).
5. A system according to claim 1, wherein the said first calculation means (3) are adapted to determine a service level agreement usage predictive profile constituting said network usage predictive state from said service level agreement usage profiles (7); and wherein said service level agreement usage predictive profile from said third data and said service level agreement usage profiles.
6. A system according to claim 1, characterized in that said first data is chosen in a group comprising the current usage of resources andor services of the network and at least a portion of the record of usage of the resources andor services of said network.
7. A system according to claim 5, characterized in that said first calculation means (3) are adapted to determine said service level agreement usage profiles (7) by means of a trend evolution analysis.
8. A system according to claim 1, characterized in that said third data is chosen in a group comprising the future types of service level agreements and the future evolution of service subscriptions.
9. A system according to claim 1, characterized in that said second calculation means (4) include traffic engineering means (12) adapted to determine an optimum configuration of the network from said second data describing the plant (Ri, ERj) of said network and a usage predictive state and predictive state validation means (11) adapted i) to supply said traffic engineering means (12) with said predictive state delivered by said first calculation means (3) and ii) on receiving an optimum configuration associated with said predictive state to determine whether said network can support said optimum configuration or not and then, if it cannot, to determine the network plant liable to be disturbed by the evolution of the network corresponding to said predictive state.
10. A system according to claim 9, characterized in that said second calculation means (4) include planning determination means (13) connected to a planning database (14) and adapted to determine said planning proposal from the designation of the disturbed plant and said planning data from said database.
11. A system according to claim 10, characterized in that said planning determination means (13) are adapted to deliver a planning proposal minimizing the costs of network evolution.
12. A system according to claim 10, characterized in that at least some of said planning data takes the form of planning rules.
13. A system according to claim 10, characterized in that said planning determination means (13) are adapted, before delivering said planning proposal, to supply said traffic engineering means (12) so that they determine a new optimum configuration corresponding to said network evolution planning proposal and said validation means (11) are adapted, on receiving a new optimum configuration associated with said planning proposal, to determine if said network, as defined by said planning proposal, can support said new optimum configuration or not and then, if it can, to send to said planning determination means (13) an authorization to deliver said planning proposal and, if it cannot, to determine the network plant liable to be disturbed by said planning proposal and to send to said planning determination means (13) the designation of said disturbed plant for them to determine a new planning proposal.
14. A system according to claim 1, characterized in that it includes a graphical user interface (5) adapted to enable the definition of said third data by an operator and the display of each planning proposal.
15. A system according to claim 13, characterized in that it includes a graphical user interface (5) adapted to enable the definition of said third data by an operator and the display of each planning proposal, wherein said graphic user interface (5) is adapted to enable an operator to monitor the validation of planning proposals.
16. A system (2) for managing a communication network, characterized in that it includes a processing system (1) according to claim 1.
17. A method of processing communication network configuration data, characterized in that it consists in determining i) a network usage predictive state from first data representative of the usage of resources andor services within said network and ii) a network evolution planning proposal from said usage predictive state and second data representative of plant (Ri, ERj) of said network, and in that usage profiles of service level agreements (7) between the operator of the network and customers are determined from said first data and said service level agreements.
18. A method according to claim 17, characterized in that said network usage predictive state is determined from complementary third data representative of user requirement prediction information.
19. Use of a method, a processing system (1), and a management system (2) according to claim 1 in networks chosen in a group comprising Internet (IP), MPLSGMPLS, ATM and Frame Relay networks.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound having the formula:
wherein,
Q is (CHR6)1-3;
R1 and each R6 is, independently, H, optionally substituted C1-6 alkyl, optionally substituted C1-4 alkaryl, optionally substituted C1-4 alkheterocyclyl, or optionally substituted C2-9 heterocyclyl;
each of R2 and R3 is, independently, H, Hal, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-6 alkaryl, optionally substituted C2-9 heterocyclyl, hydroxy, optionally substituted C1-6 alkoxy, optionally substituted C1-6 thioalkoxy, (CH2)r2NHC(NH)R2A, or (CH2)r2NHC(S)NHR2A, or optionally substituted C1-4 alkheterocyclyl,
wherein r2 is an integer from 0 to 2, R2A is optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-4 alkaryl, optionally substituted C2-9 heterocyclyl, optionally substituted C1-4 alkheterocyclyl, optionally substituted C1-6 thioalkoxy, optionally substituted C1-4 thioalkaryl, optionally substituted aryloyl, optionally substituted C1-4 thioalkheterocyclyl, or optionally substituted amino;
each of R4 and R5 is independently H, Hal, (CH2)r2NHC(NH)R2A, or (CH2)r2NHC(S)NHR2A;
wherein Y1 and Y2 are each H, or Y1 and Y2 together are \u2550O, or Y1 and Y2 are independently H, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-6 alkaryl, optionally substituted C2-9 heterocyclyl, hydroxy, optionally substituted C1-6 alkoxy, optionally substituted C1-6 thioalkoxy, or optionally substituted C1-4 alkheterocyclyl;
wherein only one of R2, R3, R4, and R5 is (CH2)r2NHC(NH)R2A or (CH2)24NHC(S)NH2A;
or a pharmaceutically acceptable salt or prodrug thereof.
2. The compound of claim 1,
wherein,
Q is (CHR6)1-3;
R1 and each R6 is, independently, H, optionally substituted C1-6 alkyl, optionally substituted C1-4 alkaryl, optionally substituted C1-4 alkheterocyclyl, or optionally substituted C2-9 heterocyclyl;
each of R2 and R3 is, independently, H, Hal, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-6 alkaryl, optionally substituted C2-9 heterocyclyl, or optionally substituted C1-4 alkheterocyclyl;
each of R4 and R5 is, independently, H, (CH2)r2NHC(NH)R2A, or (CH2)r2NHC(S)NHR2A
wherein Y1 and Y2 are each H, or Y1 and Y2 together are \u2550O;
wherein one, but not both, of R4 and R5 is H;
or a pharmaceutically acceptable salt or prodrug thereof.
3. The compound of claim 1, wherein Y1 and Y2 together are \u2550O, and Q is (CHR6)2.
4. The compound of claim 1, wherein Y1 and Y2 are each H, and Q is (CHR6)2.
5. The compound of claim 1, wherein Y1 and Y2 together are \u2550O, and Q is CHR6.
6. The compound of claim 1, wherein Y1 and Y2 are each H, and Q is CHR6.
7. The compound of claim 1, wherein Y1 and Y2 together are \u2550O, and Q is (CHR6)3.
8. The compound of claim 1, wherein Y1 and Y2 are each H, and Q is (CHR6)3.
9. The compound of claims 1, wherein R4 or R5 has the formula:
wherein Z is R2A.
10. The compound of claim 9, wherein R2A has the formula:
each of X1, X2, X4, and X5 is independently selected from O, S, NR7, N, or CR8; X3 is selected from N or CR8;
R7 is H or optionally substituted C1-6 alkyl;
R8 is H, Hal, optionally substituted C1-6 alkyl, hydroxy, optionally substituted C1-6 alkoxy, or optionally substituted C1-6 thioalkoxy,
wherein at least one of X1, X2, X4, and X5 is not CR8.
11. The compound of claim 10, wherein R2A has the formula:
each of X1 and X2 is independently selected from O, S, NH, N, or CH;
wherein at least one of X1 and X2 is not CH.
12. The compound of claims 1, wherein R2 or R3 has the formula:
wherein Z is R2A.
13. The compound of claim 12, wherein R2A has the formula:
each of X1, X2, X4, and X5 is independently selected from O, S, NR7, N, or CR8; X3 is selected from N or CR8;
R7 is H or optionally substituted C1-6 alkyl;
R8 is H, Hal, optionally substituted C1-6 alkyl, hydroxy, optionally substituted C1-6 alkoxy, or optionally substituted C1-6 thioalkoxy,
wherein at least one of X1, X2, X4, and X5 is not CR8.
14. The compound of claim 13, wherein R2A has the formula:
each of X1 and X2 is independently selected from O, S, NH, N, or CH;
wherein at least one of X1 and X2 is not CH.
15. The compound of claim 11, wherein X1 is CH and X2 is S.
16. The compound of claim 14, wherein X1 is CH and X2 is S.
17. The compound of claim 1, wherein said compound has the formula of:
18. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient.
19. A method of treating or preventing a condition in a mammal caused by the action of nitric oxide synthase (NOS), wherein said method comprises administering an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt or prodrug thereof to said mammal.
20. The method of claim 19, wherein said mammal is a human.
21. The method of claim 19, wherein said condition is migraine headache (with or without aura), chronic tension type headache (CTTH), migraine with allodynia, medication overuse headache, neuropathic pain, AIDS associated painful neuropathy, chronic headache, central post-stroke pain (CPSP), medication-induced hyperalgesia or allodynia, acute pain, chronic pain, diabetic neuropathy, trigeminal neuralgia, chemotherapy induced neuropathic pain, bone cancer pain, chemical dependencies or addictions, CNS disorders, neurodegenerative diseases or nerve injury, cardiovascular related conditions, diabetic nephropathy, inflammatory diseases, or gastrointestinal disorders.
22. The method of claim 21, wherein said medication-induced hyperalgesia or allodynia is opioid-induced hyperalgesiaallodynia or triptan (5-HT1D1B agonists)-induced hyperalgesia or allodynia.
23. The method of claim 21, wherein said chemotherapy induced neuropathic pain is induced by Paclitaxol, cis-Platin, or Doxorubicin.
24. The method of claim 21, wherein said chemical dependency or addiction is drug addiction, cocaine addiction, nicotine addiction, methamphetamine-induced neurotoxicity, ethanol tolerance, dependence, or withdrawal, or morphineopioid induced tolerance, dependence, hyperalgesia, or withdrawal.
25. The method of claim 21, wherein said CNS disorder is epilepsy, anxiety, depression, attention deficit hyperactivity disorder (ADHD), psychosis, or dementia.
26. The method of claim 21, wherein said neurodegenerative disease or nerve injury is acute spinal cord injury, AIDS associated dementia, Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, multiple sclerosis, neurotoxicity, or head trauma.
27. The method of claim 21, wherein said cardiovascular related condition is stroke, coronary artery bypass graft (CABG) associated neurological damage, hypothermic cardiac arrest (HCA), post-stroke pain, cardiogenic shock, reperfusion injury, or vascular dementia.
28. The method of claim 21, wherein said inflammatory disease is osteoarthritis or neuroinflammation.
29. The method of claim 21, wherein said gastrointestinal disorder is ileostomy-associated diarrhea, dumping syndrome, or visceral pain.
30. The method of claim 21, wherein said condition is stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, chronic tension type headache, neuropathic pain, central post-stroke pain (CPSP), morphineopioid induced hyperalgesia or chronic pain.
31. The method of claim 19, wherein said condition is central post-stroke pain (CPSP).
32. The method of claim 19, wherein said method further comprises administering to said mammal an opioid.
33. The method of claim 32, wherein said opioid is alfentanil, butorphanol, buprenorphine, dextromoramide, dezocine, dextropropoxyphene, codeine, dihydrocodeine, diphenoxylate, etorphine, fentanyl, hydrocodone, hydromorphone, ketobemidone, loperamide, levorphanol, levomethadone, meperidine, meptazinol, methadone, morphine, morphine-6-glucuronide, nalbuphine, naloxone, oxycodone, oxymorphone, pentazocine, pethidine, piritramide, propoxyphene, remifentanil, sulfentanyl, tilidine, and tramadol.
34. The method of claim 19, wherein said method further comprises administering to said mammal an antidepressant.
35. The method of claim 34, wherein said antidepressant is a selective serotonin re-uptake inhibitor.
36. The method of claim 35, wherein said selective serotonin re-uptake inhibitor is citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline.
37. The method of claim 34, wherein said antidepressant is a norepinephrine-reuptake inhibitor.
38. The method of claim 37, wherein said norepinephrine-reuptake inhibitor is amitriptyline, desmethylamitriptyline, clomipramine, doxepin, imipramine, imipramine oxide, trimipramine; adinazolam, amiltriptylinoxide, amoxapine, desipramine, maprotiline, nortriptyline, protriptyline, amineptine, butriptyline, demexiptiline, dibenzepin, dimetacrine, dothiepin, fluacizine, iprindole, lofepramine, melitracen, metapramine, norclolipramine, noxiptilin, opipramol, perlapine, pizotyline, propizepine, quinupramine, reboxetine, or tianeptine.
39. The method of claim 34, wherein said antidepressant is a selective noradrenalinenorepinephrine reuptake inhibitor.
40. The method of claim 39, wherein selective noradrenalinenorepinephrine reuptake inhibitor is atomoxetine, bupropion, reboxetine, or tomoxetine.
41. The method of claim 34, wherein said antidepressant is a dual serotoninnorepinephrine reuptake inhibitor.
42. The method of claim 41, wherein said dual serotoninnorepinephrine reuptake inhibitor is duloxetine, milnacipran, mirtazapine, nefazodone, or venlafaxine.
43. The method of claim 34, wherein said antidepressant is a monoamine oxidase inhibitor.
44. The method of claim 43, wherein said monoamine oxidase inhibitor is amiflamine, iproniazid, isocarboxazid, M-3-PPC (Draxis), moclobemide, pargyline, phenelzine, tranylcypromine, or vanoxerine.
45. The method of claim 34, wherein said antidepressant is a reversible monoamine oxidase type A inhibitor.
46. The method of claim 45, wherein said reversible monoamine oxidase type A inhibitor is bazinaprine, befloxatone, brofaromine, cimoxatone, or clorgyline.
47. The method of claim 34, wherein said antidepressant is a tricyclic.
48. The method of claim 47, wherein said tricyclic is amitriptyline, clomipramine, desipramine, doxepin, imipramine, maprotiline, nortriptyline, protriptyline, or trimipramine.
49. The method of claim 34, wherein said antidepressant is adinazolam, alaproclate, amineptine, amitriptylinechlordiazepoxi-de combination, atipamezole, azamianserin, bazinaprine, befuraline, bifemelane, binodaline, bipenamol, brofaromine, caroxazone, cericlamine, cianopramine, cimoxatone, citalopram, clemeprol, clovoxamine, dazepinil, deanol, demexiptiline, dibenzepin, dothiepin, droxidopa, enefexine, estazolam, etoperidone, femoxetine, fengabine, fezolamine, fluotracen, idazoxan, indalpine, indeloxazine, iprindole, levoprotiline, lithium, litoxetine; lofepramine, medifoxamine, metapramine, metralindole, mianserin, milnacipran, minaprine, mirtazapine, montirelin, nebracetam, nefopam, nialamide, nomifensine, norfluoxetine, orotirelin, oxaflozane, pinazepam, pirlindone, pizotyline, ritanserin, rolipram, sercloremine, setiptiline, sibutramine, sulbutiamine, sulpiride, teniloxazine, thozalinone, thymoliberin, tianeptine, tiflucarbine, trazodone, tofenacin, tofisopam, toloxatone, tomoxetine, veralipride, viloxazine, viqualine, zimelidine, or orzometrapine.
50. The method of claim 19, wherein said method further comprises administering to said mammal an antiepileptic.
51. The method of claim 50, wherein said antiepileptic is carbamazepine, flupirtine, gabapentin, lamotrigine, oxcarbazepine, phenyloin, retigabine, topiramate, or valproate.
52. The method of claim 19, wherein said method further comprises administering to said mammal a non-steroidal anti-inflammatory drug (NSAID) or acetaminophen.
53. The method of claim 52, wherein said NSAID is acemetacin, aspirin, celecoxib, deracoxib, diclofenac, diflunisal, ethenzamide, etofenamate, etoricoxib, fenoprofen, flufenamic acid, flurbiprofen, lonazolac, lornoxicam, ibuprofen, indomethacin, isoxicam, kebuzone, ketoprofen, ketorolac, naproxen, nabumetone, niflumic acid, sulindac, tolmetin, piroxicam, meclofenamic acid, mefenamic acid, meloxicam, metamizol, mofebutazone, oxyphenbutazone, parecoxib, phenidine, phenylbutazone, piroxicam, propacetamol, propyphenazone, rofecoxib, salicylamide, suprofen, tiaprofenic acid, tenoxicam, valdecoxib, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide, N-2-(cyclohexyloxy)-4-nitrophenylmethanesulfonamide, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-4-(methylsulfonyl)phenyl-3(2H)-pyridazinone, and 2-(3,5-difluorophenyl)-3-4-(methylsulfonyl)phenyl-2-cyclopenten-1-one).
54. The method of claim 19, wherein said method further comprises administering to said mammal an antiarrhythmic.
55. The method of claim 19, wherein said method further comprises administering to said mammal a GABA-B antagonist.
56. The method of claim 19, wherein said method further comprises administering to said mammal an alpha-2-adrenergic receptor agonist.
57. The method of claim 19, wherein said method further comprises administering to said mammal a serotonin 5HT1B1D agonist.
58. The method of claim 57, wherein said serotonin 5HT1B1D agonist is eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, donitriptan, or zolmitriptan.
59. The method of claim 19, wherein said method further comprises administering to said mammal an N-methyl-D-aspartate antagonist or glutamate receptor antagonist.
60. The method of claim 59, wherein said N-methyl-D-aspartate antagonist or glutamate receptor antagonist is amantadine; aptiganel; besonprodil; budipine; conantokin G; delucemine; dexanabinol; dextromethorphan; dextropropoxyphen; felbamate; fluorofelbamate; gacyclidine; glycine; ipenoxazone; kaitocephalin; ketamine; ketobemidone; lanicemine; licostinel; midafotel; memantine; D-methadone; D-morphine; milnacipran; neramexane; orphenadrine; remacemide; sulfazocine; FPL-12,495 (racemide metabolite); topiramate; (\u03b1R)-\u03b1-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid; 1-aminocyclopentane-carboxylic acid; 5-(aminomethyl)-2-(5S)-9-chloro-2,3,6,7-tetrahydro-2,3-dioxo-1H,5H-pyrido1,2,3-dequinoxalin-5-ylacetylaminophenoxy-acetic acid; \u03b1-amino-2-(2-phosphonoethyl)-cyclohexanepropanoic acid; \u03b1-amino-4-(phosphonomethyl)-benzeneacetic acid; (3E)-2-amino-4-(phosphonomethyl)-3-heptenoic acid; 3-(1E)-2-carboxy-2-phenylethenyl-4,6-dichloro-1H-indole-2-carboxylic acid; 8-chloro-2,3-dihydropyridazino4,5-bquinoline-1,4-dione 5-oxide salt with 2-hydroxy-N,N,N-trimethyl-ethanaminium; N\u2032-2-chloro-5-(methylthio)phenyl-N-methyl-N-3-(methylthio)phenyl-guanidine; N\u2032-2-chloro-5-(methylthio)phenyl-N-methyl-N-3-(R)-methylsulfinylphenyl-guanidine; 6-chloro-2,3,4,9-tetrahydro-9-methyl-2,3-dioxo-1H-indeno1,2-bpyrazine-9-acetic acid; 7-chlorothiokynurenic acid; (3S,4aR,6S,8aR)-decahydro-6-(phosphonomethyl)-3-isoquinolinecarboxylic acid; (\u2212)-6,7-dichloro-1,4-dihydro-5-3-(methoxymethyl)-5-(3-pyridinyl)-4-H-1,2,4-triazol-4-yl-2,3-quinoxalinedione; 4,6-dichloro-3-(E)-(2-oxo-1-phenyl-3-pyrrolidinylidene)methyl-1H-indole-2-carboxylic acid; (2R,4S)-rel-5,7-dichloro-1,2,3,4-tetrahydro-4-(phenylamino)carbonylamino-2-quinolinecarboxylic acid; (3R,4S)-rel-3,4-dihydro-3-4-hydroxy-4-(phenylmethyl)-1-piperidinyl-2H-1-benzopyran-4,7-diol; 2-(2,3-dihydro-1H-inden-2-yl)amino-acetamide; 1,4-dihydro-6-methyl-5-(methylamino)methyl-7-nitro-2,3-quinoxalinedione; 2-(8,9-dioxo-2,6-diazabicyclo5.2.0non-1(7)-en-2-yl)ethyl-phosphonic acid; (2R,6S)-1,2,3,4,5,6-hexahydro-3-(2S)-2-methoxypropyl-6,11,11-trimethyl-2,6-methano-3-benzazocin-9-ol; 2-hydroxy-5-(pentafluorophenyl)methylamino-benzoic acid; 1-2-(4-hydroxyphenoxy)ethyl-4-(4-methylphenyl)methyl-4-piperidinol; 1-4-(1H-imidazol-4-yl)-3-butynyl-4-(phenylmethyl)-piperidine; 2-methyl-6-(phenylethynyl)-pyridine; 3-(phosphonomethyl)-L-phenylalanine; or 3,6,7-tetrahydro-2,3-dioxo-N-phenyl-1H,5H-pyrido1,2,3-dequinoxaline-5-acetamide.
61. The method of claim 19, wherein said method further comprises administering to said mammal a cholecystokinin B antagonist.
62. The method of claim 19, wherein said method further comprises administering to said mammal a substance P antagonist.
63. The method of claim 19, wherein said method further comprises administering to said mammal an anti-inflammatory compound.
64. The method of claim 63, wherein said anti-inflammatory compound is aspirin, celecoxib, cortisone, deracoxib, diflunisal, etoricoxib, fenoprofen, ibuprofen, ketoprofen, naproxen, prednisolone, sulindac, tolmetin, piroxicam, mefenamic acid, meloxicam, phenylbutazone, rofecoxib, suprofen, valdecoxib, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide, N-2-(cyclohexyloxy)-4-nitrophenylmethanesulfonamide, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-4-(methylsulfonyl)phenyl-3(2H)-pyridazinone, or 2-(3,5-difluorophenyl)-3-4-(methylsulfonyl)phenyl-2-cyclopenten-1-one.
65. The method of claim 19, wherein said method further comprises administering to said mammal a DHP-sensitive L-type calcium channel antagonist, omega-conotoxin-sensitive N-type calcium channel antagonist, or a PQ-type calcium channel antagonist.
66. The method of claim 19, wherein said method further comprises administering to said mammal an adenosine kinase antagonist.
67. The method of claim 19, wherein said method further comprises administering to said mammal an adenosine receptor A1 agonist, an adenosine receptor A2a antagonist or an adenosine receptor A3 agonist.
68. The method of claim 19, wherein said method further comprises administering to said mammal an adenosine deaminase inhibitor.
69. The method of claim 19, wherein said method further comprises administering to said mammal an adenosine nucleoside transport inhibitor.
70. The method of claim 19, wherein said method further comprises administering to said mammal a vanilloid VR1 receptor agonist.
71. The method of claim 19, wherein said method further comprises administering to said mammal a cannabinoid CB1CB2 agonist.
72. The method of claim 19, wherein said method further comprises administering to said mammal an AMPA receptor antagonist.
73. The method of claim 19, wherein said method further comprises administering to said mammal a kainate receptor antagonist.
74. The method of claim 19, wherein said method further comprises administering to said mammal a sodium channel blocker.
75. The method of claim 19, wherein said method further comprises administering to said mammal a nicotinic acetylcholine receptor agonist.
76. The method of claim 19, wherein said method further comprises administering to said mammal a KATP potassium channel, Kv1.4 potassium channel, Ca2+-activated potassium channel, SK potassium channel, BK potassium channel, IK potassium channel, or KCNQ23 potassium channel opening agent.
77. The method of claim 19, wherein said method further comprises administering to said mammal a muscarinic M3 antagonist, a muscarinic M1 agonist, or a muscarinic M2M3 partial agonistantagonist.
78. The method of claim 19, wherein said method further comprises administering to said mammal an antioxidant.
79. The method of claim 19, wherein said method further comprises administering to said mammal an antipsychotic agent.
80. The method of claim 79, wherein said antipsychotic agent is promazine, chlorpromazine, chlorprothixene, thioridazine, acetophenazine, mesoridazine, droperidol, loxapine, molindone, perphenazine, prochlorphenazine, thiothixene, trifluoperazine, fluphenazine, pimozide, flupenthixol, methotrimeprazine, pipotiazine, sertindole, clozapine, olanzapine, risperidone, aripiprazole, quetiapine, haloperidol, ziprasidone, or iloperidone.
81. The method of claim 19, wherein said method further comprises administering to said mammal a dopamine receptor antiparkinson’s agent
82. The method of claim 81, wherein said antiparkinson’s agent is levodopa, or pramipexole.
83. The method of claim 19, wherein said method further comprises administering to said mammal Fatty Acid Amide Hydrolase (FAAH) Inhibitor.

1. A machine for connecting elongate metal profiles with at least one plastic strip, said machine comprising:
an elongate support table for supporting a pair of elongate metal profiles to be connected, said table forming a table top and an elongate slot extending longitudinally along said table top, said table top being divided by said slot into an inner top section for supporting an elongate first metal profile and an outer top section for supporting an elongate second metal profile so that, during use of said machine, the first and second metal profiles are horizontally spaced from one another;
a horizontal, elongate support beam extending along one side of said support table and having a top and a bottom;
means for supporting opposite ends of said support beam in an elevated position;
a support carriage mounted for horizontal movement lengthwise along the support beam;
a first drive system for moving said support carriage horizontally along said support beam firstly in a front end to rear end direction to pull at least one plastic strip between said first and second profiles and secondly in a rear end to front end direction to clamp opposite edges of said at least one plastic strip to said first and second profiles;
top and bottom tool heads each mounted on said support carriage for vertical movement thereon, the top tool head mounted above said support table and above said bottom tool head, the bottom tool head mounted below said support table;
two further drive systems for respectively moving said tool heads vertically on said support carriage;
a strip puller mechanism mounted on said tool heads for horizontal movement therewith, said strip puller mechanism being adapted to engage and hold at least one end section of said at least one plastic strip prior to and during the pulling of said at least one plastic strip between said first and second profiles; and
a pair of clamping rollers rotatably mounted on each tool head for respectively engaging and bending longitudinal connecting flanges extending along the lengths of said first and second profiles in order to connect said at least one plastic strip to these profiles.
2. The machine according to claim 1 including at least one rotatable knurling tool mounted on each tool head so as to be vertically movable on its respective tool head, wherein said machine is adapted to carry out a knurling operation on said longitudinal connecting flanges as said at least one plastic strip is pulled between the first and second profiles.
3. The machine according to claim 2 wherein the or each knurling tool has a knurling wheel made to imprint at least one connecting flange rollably engaged by the knurling wheel with knurls in a non-cutting manner.
4. The machine according to claim 1 wherein said strip pulling mechanism comprises two electrical drills each mounted on a respective one of said tool heads and two linear actuators each operatively connected to a respective one of the drills and adapted to move its respective drill vertically in order to move the drill from a disengaged, retracted position to drilling positions, whereby each drill is able to drill through the end section of a respective one of two plastic strips so that a drill bit of the drill can be used to pull said one plastic strip.
5. The machine according to claim 1 wherein each of said further drive systems for moving a respective one of the tool heads is spring loaded so as to bias the respective clamping rollers on said one tool head into engagement with the adjacent longitudinal connecting flanges of the profiles during use of the machine.
6. The machine according to claim 1 wherein each further drive system for moving a respective one of the tool heads includes at least one ball screw which extends substantially vertically and at least one servomotor for turning said at least one ball screw, and wherein the or each servomotor has its own gear box which is mounted on its respective tool head.
7. The machine according to claim 1 including two spaced-apart rotatable knurling tools mounted on each tool head so as to be vertically movable relative to their respective tool head, two vertical linear actuators mounted on each tool head for moving the two knurling tools vertically, and means mounted on each tool head for biasing each of the two knurling tools horizontally into engagement with a respective pair of the longitudinal connecting flanges, wherein the horizontal position of each knurling tool is determined by pressure between the respective knurling tool and said pair of longitudinal connecting flanges engaged thereby during a knurling operation by said machine.
8. The machine according to claim 1 including a profile guide and support assembly mounted on said top tool head, said guide assembly including two spaced-apart support members, spaced-apart roller bearings mounted on each of support members, and motor means for adjustably moving the two support members towards or away from each other, wherein said guide and support assembly allows the machine to accommodate first and second metal profiles of different sizes, these profiles during use of the machine being mounted between the two support members and engaged and supported by said roller bearings.
9. A machine for knurling and connecting elongate, first and second metal profiles, said machine comprising:
an elongate support table for supporting and holding said first and second metal profiles so that they are spaced apart from one another a predetermined distance;
a horizontal, elongate support member extending along the support table in its lengthwise direction;
a single support carriage mounted for movement along the length of the support member;
a tool head system mounted on said support carriage for vertical movement thereon;
a motor drive for moving said support carriage horizontally along said support member in said lengthwise direction;
a drive system for moving said tool head system vertically;
clamping rollers rotatably mounted on said tool head system for respectively engaging and bending longitudinal connecting flanges extending along the lengths of said first and second profiles in order to connect same by at least one plastic connecting strip inserted between the profiles; and
rotatable knurling tools mounted on said tool head system so as to be vertically movable relative to the tool head system and adapted to carry out a knurling operation on said longitudinal connecting flanges prior to the bending of said longitudinal connecting flanges by said clamping rollers.
10. The machine according to claim 9 wherein said tool head system includes top and bottom tools heads each mounted for vertical movement on said support carriage, the top tool head being mounted above said support table and the bottom tool head being mounted below said support table, and wherein two of said knurling tools are mounted on each tool head so as to be vertically movable relative to their respective tool head.
11. The machine according to claim 10 wherein each knurling tool has a knurling wheel made to imprint a respective two of said longitudinal connecting flanges by means of a rolling, non-cutting engagement.
12. The machine according to claim 10 including two vertical linear actuators mounted on each tool head for moving the two knurling tools vertically and means mounted on each tool head for biasing each of the two knurling tools horizontally into engagement with a respective pair of the longitudinal connecting flanges, wherein the horizontal position of each knurling tool is determined by pressure between the respective knurling tool and said pair of longitudinal connecting flanges engaged thereby during a knurling operation by said machine.
13. The machine according to claim 9 including an adjustable profile guide and support assembly, said guide and support assembly including two spaced-apart, elongate support members, spaced-apart roller bearings mounted on each of said support members, and actuator means for adjustably moving the two support members towards or away from each other.
14. A machine for connecting elongate first and second metal profiles with at least one plastic strip, said machine comprising:
an elongate support table arrangement for supporting and holding said first and second metal profiles in fixed, spaced-apart positions;
a support carriage system including a support carriage mounted for powered movement lengthwise along said support table arrangement;
a tool head system mounted on said support carriage for vertical movement thereon;
a linear drive system for moving said tool head system vertically;
clamping rollers rotatably mounted on said tool head system for respectively engaging and bending longitudinal connecting flanges extending along the lengths of said first and second profiles in order to connect same by clamping each longitudinal edge of each plastic strip between a respective pair of said connecting flanges; and
at least one pulling mechanism mounted on said tool head system for horizontal movement therewith, said at least one pulling mechanism including at least one power drill adapted to hold and turn a drill bit,
wherein, during use of said machine, said at least one power drill fitted with said drill bit can drill through and hold an end section of said at least one plastic strip in order to pull said at least one plastic strip between the first and second profiles.
15. The machine according to claim 14 wherein there are two of said at least one pulling mechanism, each of which has one of said at least one power drill, said tool head system includes top and bottom tool heads each mounted for vertical movement on said support carriage and mounted respectively above and below said support table arrangement, and each power drill is mounted on a respective one of said tool heads.
16. The machine according to claim 15 including a linear actuator for moving a respective one of the power drills vertically from a disengaged, retracted position to drilling positions.
17. The machine according to claim 16 wherein said support table arrangement includes a support table forming a table top and an elongate slot extending longitudinally along said table top, said table top being divided by said slot into an inner top section for supporting said first metal profile and an outer top section for supporting said second metal profile so that it is horizontally spaced from the first metal profile.
18. The machine according to claim 15 including two rotatable knurling tools mounted on each of said tool heads, each knurling tool being vertically movable on its respective tool head, wherein said machine can carry out a knurling operation on said longitudinal connecting flanges as said at least one plastic strip is pulled between the first and second metal profiles.
19. The machine according to claim 15 wherein each power drill is a high speed electric drill and each is adapted to drill through and hold the end section of a respective one of two plastic strips, whereby the two power drills and their drill bits can pull the two plastic strips simultaneously between the first and second metal profiles.
20. The machine according to claim 19 wherein including air cylinder actuators, each operatively connected to a respective one of said power drills in order to move the power drill vertically from a disengaged; retracted position to drilling positions.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A display device, comprising:
a display substrate;
a display unit disposed on the display substrate;
a sealing substrate affixed to the display substrate by an adhering layer located outside an outer periphery of the display unit, the sealing substrate located outside of a display area of the display substrate, the sealing substrate including a composite member including a resin and a plurality of carbon fibers and an insulating member affixed to the composite member, the insulating member including a plurality of first through holes through the insulating member;
a metal film disposed at one side of the sealing substrate, facing the display substrate; and
a conductive connection portion contacting the metal film through a plurality of second through holes through the sealing substrate;
wherein the insulating member is affixed to the composite member at a peripherally outward side of at least three peripheral edges of the composite member, and
wherein the adhering layer includes a first non-conductive adhering layer located outside the outer periphery of the display unit, a second non-conductive adhering layer located peripherally outward from the first non-conductive adhering layer, and a conductive adhering layer between the first non-conductive adhering layer and the second non-conductive adhering layer.
2. The display device as claimed in claim 1, wherein the carbon fibers cross each other in the resin.
3. The display device as claimed in claim 1, wherein the composite member includes a plurality of layers, each of the plurality of layers including a resin and a plurality of carbon fibers, wherein a plurality of carbon fibers arranged in at least one of the plurality of layers and a plurality of carbon fibers arranged in at least another layer among the plurality of layers cross each other.
4. The display device as claimed in claim 1, further comprising:
a first conductive portion extending between inner and outer sides of the insulating member through the plurality of first through holes and receiving a first electric signal; and
a second conductive portion extending between inner and outer sides of the composite member through the plurality of second through holes and receiving a second electric signal.
5. The display device as claimed in claim 1, wherein the insulating member is affixed to the composite member at a peripherally outward side of all peripheral edges of the composite member.
6. The display device as claimed in claim 5, further comprising:
a first conductive portion extending between inner and outer sides of the insulating member through the plurality of first through holes and receiving a first electric signal; and
a second conductive portion extending between an inner side of the insulating member, an inner side of the composite member, and an outer side of the insulating member through the plurality of second through holes and receiving a second electric signal.
7. The display device as claimed in claim 1, wherein the composite member includes a protrusion at a side surface that faces the insulating member, and the insulating member includes a groove receiving the protrusion.
8. The display device as claimed in claim 1, wherein the composite member includes a plurality of protruding portions spaced apart from each other at a side surface facing the insulating member, and the insulating member includes a plurality of recess portions receiving the protruding portions.
9. The display device as claimed in claim 1, wherein the insulating member further includes an insulating plate covering an external surface of the composite member.
10. The display device of claim 1, wherein the insulating member further includes a protection portion that protectively covers the adhering layer and a side surface of the display substrate.
11. The display device as claimed in claim 1, wherein the insulating member is a plastic injection molded material.
12. The display device as claimed in claim 11, wherein the insulating member includes a negative thermal expansion filler.
13. The display device as claimed in claim 1, wherein the metal film includes at least one of an aluminum film, an aluminum alloy film, a copper film, and a copper alloy film.
14. An organic light emitting diode (OLED) display, comprising:
a display substrate;
a display unit disposed on the display substrate and including a common power line and a common electrode;
a sealing substrate affixed to the display substrate by at least one adhering layer located outside an outer periphery of the display unit, the sealing substrate located outside of a display area of the display substrate, the sealing substrate including first and second through holes through the sealing substrate;
a first conductive portion disposed on inner and outer sides of the sealing substrate and extending through the first through holes, the first conductive portion supplying a first electric signal to the common power line; and
a second conductive portion disposed on the inner and outer sides of the sealing substrate and extending through the second through holes, the second conductive portion supplying a second electric signal to the common electrode,
wherein the sealing substrate includes,
a composite member including a resin and a plurality of carbon fibers, and
an insulating member attached to the composite member and including at least one through hole among the first and second through holes;
wherein the insulating member is attached to the composite member at peripherally outward sides of at least three peripheral edges of the composite member, and wherein the insulating member includes the first through holes, and the composite member includes the second through holes, and
wherein the at least one adhering layer includes a first non-conductive adhering layer located outside the outer periphery of the display unit, a second non-conductive adhering layer located peripherally outward from the first non-conductive adhering layer, and a conductive adhering layer between the first non-conductive adhering layer and the second non-conductive adhering layer.
15. The OLED display as claimed in claim 14, further comprising:
a pad unit disposed peripherally outward from the display unit, and including a first pad connected with the common power line and a second pad connected with the common electrode; and
the conductive adhering layer is disposed between the first pad and the first conductive portion and between the second pad and the second conductive portion.
16. The OLED display as claimed in claim 15, wherein the common power line includes a first common power line and a second common power line that cross each other, and wherein the pad unit includes a plurality of the first pad and the second pad iteratively alternated along one direction of the display substrate.
17. The OLED display as claimed in claim 15, wherein the conductive adhering layer is electrically conductive in the thickness direction and electrically insulating in directions other than the thickness direction.
18. The OLED display as claimed in claim 14, further comprising a first pad disposed at an outer side of the display unit and the conductive adhering layer is disposed between the first pad and the first conductive portion, and wherein the second conductive portion is directly attached to the common electrode.
19. The OLED display as claimed in claim 18, further comprising a plurality of spacers disposed at a lower portion of the common electrode,
wherein the common electrode includes protruding portions corresponding to the spacers and contacting the second conductive portion.
20. The OLED display as claimed in claim 14, wherein the first conductive portion includes a first inner layer disposed at the inner side of the insulating member, a first connection portion extending through the first through hole, and a first outer layer disposed at the outer side of the insulating member, and wherein the second conductive portion includes a second inner layer formed at the inner side of the composite member, a second connection portion filled in the second through hole, and a second outer layer formed at the outer side of the composite member.
21. The OLED display as claimed in claim 14, wherein the insulating member is attached to the composite member at a peripherally outward side of the edges of the composite member, and wherein the insulating member includes the first and second through holes.
22. The OLED display as claimed in claim 21, wherein the first conductive portion includes a first inner layer at the inner side of the insulating member, a first connection portion that fills the first through hole, and a first outer layer at the outer side of the insulating member, and the second conductive portion includes a second inner layer at the inner side of the insulating member and the inner side of the composite member, a second connection portion that fills the second through hole, and a second outer layer at the outer side of the insulating member.
23. The OLED display as claimed in claim 22, wherein the second inner layer includes a metal foil having an oxide film formed by anodizing at one side thereof, facing the composite member.
24. The OLED display as claimed in claim 14, wherein the insulating member is made of a plastic injection molded material.
25. The OLED display as claimed in claim 24, wherein the insulating member includes a negative thermal expansion filler.
26. The OLED display as claimed in claim 24, wherein the composite member includes a protrusion at a side surface thereof, facing the insulating member, and the insulating member includes a groove that receives the protrusion.
27. The OLED display as claimed in claim 24, wherein the composite member includes a plurality of protruding portions spaced apart from each other at a side surface, facing the insulating member and the insulating member includes recess portions receiving the protruding portions.
28. The OLED display as claimed in claim 24, wherein the insulating member further includes an insulating plate covering an external surface of the composite member.
29. The OLED display as claimed in claim 24, wherein the insulating member further includes a protection portion covering the adhering layer and the display substrate along the thickness direction.